Prostanoid IP Receptor Antagonists for Ocular Surface Nociception
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular surface discomfort and pain, such as dry-eye disease, surgical pain, and corneal injuries, are inadequate, with existing medications like NSAIDs and Cyclo-oxygenase inhibitors having limited efficacy and side effects, and there is a lack of therapeutic interventions that effectively attenuate nociceptive stimulation and neurotransmission at the ocular surface.
Innovation Solution
The use of prostanoid IP receptor antagonists, specifically compounds like 4,5-dihydro-N-[4-[[4-(1-methylethoxy)phenyl]methyl]phenyl]-1H-imadazol-2-amine, which interact with prostanoid IP receptors to block the activity of pre-formed prostaglandins and provide relief from ocular surface discomfort and pain by administering them in ophthalmologically acceptable compositions such as solutions, emulsions, or gels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NSAIDs are used to treat ocular surface discomfort, then some pain relief is achieved, but they are much less effective in reversing ongoing conditions because they only block new synthesis of prostanoids leaving pre-existing ocular prostanoids to still interact with receptors
Solution Approach 1:
The patent extracts and isolates the specific IP receptor pathway from the general prostanoid system. By using selective IP receptor antagonists (such as SC-57752, ONO-8711, and ONO-1714) rather than broad-spectrum NSAIDs, the invention selectively blocks only the prostacyclin IP receptor pathway that mediates ocular surface nociception, while leaving other prostanoid pathways intact. This selective extraction of the problematic pathway resolves the contradiction by directly blocking pre-existing prostanoid activity at the receptor level.
Solution Approach 2:
The patent changes the therapeutic parameter from blocking prostanoid synthesis (COX inhibition) to blocking prostanoid receptor activation (IP receptor antagonism). This parameter change allows the drug to directly interact with and block pre-existing prostanoids at their target receptors, providing immediate and sustained relief from ongoing ocular surface discomfort, thereby resolving the limitation of NSAIDs that only block new synthesis.
2Reliability
If topical steroids are used for post-surgical pain relief, then pain is reduced, but long term use is associated with severe side effects
Solution Approach 1:
The patent applies local quality by using selective IP receptor antagonists that specifically target the prostacyclin pathway involved in ocular surface nociception without the broad anti-inflammatory effects of steroids. This localized action on the specific pain pathway provides effective pain relief while avoiding the systemic and ocular side effects associated with long-term steroid use, such as increased intraocular pressure and cataract formation.
Solution Approach 2:
The patent introduces selective IP receptor antagonists as intermediary substances that mediate pain relief by specifically blocking the IP receptor pathway. These intermediaries provide the therapeutic effect of pain reduction without triggering the harmful cascade of broad anti-inflammatory effects that lead to steroid-related side effects, thus resolving the contradiction between effectiveness and safety.
3Ease of operation
If artificial ocular surface wetting agents and lubricants are used, then some relief for ocular discomfort is provided, but there is no proven therapeutic intervention available to attenuate the nociceptive stimulation and neurotransmission at the ocular surface
Solution Approach 1:
The patent segments the approach to ocular surface discomfort into two distinct components: (1) lubrication to reduce mechanical friction and dryness, and (2) selective IP receptor antagonism to specifically block nociceptive signaling. This segmentation allows each component to address its specific function, with the IP antagonist providing the missing therapeutic intervention for attenuating nociceptive stimulation that lubricants alone cannot achieve.
Solution Approach 2:
The patent merges lubricating agents with selective IP receptor antagonists in a combined therapeutic formulation. This combination integrates the mechanical protection and comfort of lubricants with the pharmacological blockade of nociceptive pathways, thereby providing both ease of operation through lubrication and reliable attenuation of nociceptive stimulation through receptor antagonism, resolving the identified gap in therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces ocular nociception and pain associated with dry eye, corneal injuries, and surgical procedures by directly blocking the interaction of pre-formed prostaglandins with their receptors, offering sustained relief and improving ocular surface health.
Implementation Method 1
a prostanoid IP receptor antagonist... which interact with prostanoid IP receptors to block the activity of pre-formed prostaglandins
Data Source
AI summary
The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort.